שווי פעילות לרווח לפני ריבית, מסים ופחת Pharming Group (PHAR)

Pharming Group N.V. relies on stable demand within the sovereign cycle, which renders the asset defensive during a recession. The company delegates capital-intensive production and testing to partners, maintaining a lean workforce. The current EV/EBITDA multiple valuation on the GURU.Markets chart shows that 18.49 is the current metric. Meanwhile, drug filling and raw material purification are outsourced to external CMOs.

Fundamental asset screening requires an analysis of enterprise value inclusive of net debt relative to operating profit before depreciation and amortization. The current EV/EBITDA multiple valuation measures the capital payback period, while the stable cash flow from orphan drug sales at Pharming Group N.V. (PHAR) minimizes excessive leverage risks and ensures sustainable funding for new clinical trials.